+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

US Inhalation Systems Market Forecast up to 2024

  • PDF Icon


  • 98 Pages
  • January 2019
  • Region: United States
  • IHR Insights
  • ID: 4733503
10% Free customization
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

US Inhalation Systems Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024


The emergence of inhaled drug therapy has been a boon for patients with respiratory conditions such as COPD and asthma because of its painless and flexible administration when compared to injections. There are various kinds of inhalation systems available in the market, and these include inhalers and nebulizers. The tw- most commonly widespread respiratory diseases are asthma and COPD. According to WHO, around 235 million people are currently suffering from asthma, and it is very common in children.

Chronic respiratory diseases such as asthma and COPD are responsible for substantial financial and health burden in the US, and in 2015, 6.7% deaths in the US were due to chronic respiratory diseases. Chronic obstructive pulmonary disease is the third leading cause of death across the globe, accounting for approximately 3 million deaths in 2016. State of West Virginia has the highest prevalence of COPD, and around 12% of the population are diagnosed with COPD.

The US inhalation systems market is driven by an upsurge in the prevalence of respiratory diseases, increasing geriatric population, and favorable reimbursement. However, side effects allied with the drug inhalation and unattainability of single effective inhaler device that can treat many disease conditions may slow down the growth of the market in the US.

Market Analysis: The “US Inhalation Systems Market” is estimated to witness a CAGR of 5.8% during the forecast period 2018–2024. The US market is analyzed based on three segments – products, applications, and end-users.

Product Analysis: The US inhalation systems market, by product, is segmented into inhalers and nebulizers. The market by inhalers type is further segmented into dry powder inhalers and metered dose inhalers. The market by nebulizers is segmented into ultrasonic nebulizer, pneumatic nebulizer, and mesh nebulizer.

Inhalers occupied a major market share in 2017 and nebulizers segment is anticipated to grow at a high CAGR during the forecast period. The extensive usage of inhalers in the treatment of various respiratory illness such as asthma, chronic obstructive pulmonary disorder, and others makes the segment the major shareholder.

Application Analysis: The US inhalation systems market, by application, is segmented into asthma, chronic obstructive pulmonary disease (COPD), and others. Asthma occupied a major market share in 2017 and COPD is expected to grow at the highest rate in the next five years.

End-users Analysis: The US inhalation systems market by end-users is segmented into hospitals, ambulatory care centers, and home care centers. Hospitals occupied a major market share in 2017, and home care segment is expected to grow during the forecast period due to ease in the usage of modern products, less homecare cost, and the obtainability of reimbursement.

Key Players:

Omron Corp., Boehringer Ingelheim GmbH, PARI GmbH, Philips Healthcare, Teleflex Incorporated, 3M, AptarGroup, Inc., Agilent Technologies, Inc., AstraZeneca PLC, Inspir- Medical Ltd., Teva Pharmaceutical Industries Ltd., Monaghan Medical Corporation, GlaxoSmithKline plc, Becton Dickinson and Company are few of the key players in the US inhalation systems market.

Competitive Analysis:

There is an increase in approvals in recent years due to the popularity of the systems and also drug companies are launching new inhalation systems and collaborating with other vendors to develop innovative devices in the market. For instance, in February 2017, FDA approved tw- products developed by Teva Pharmaceutical Industries Ltd., ArmonAir RespiClick and AirDu- RespiClick, to treat adolescent and adult patients with asthma.

In October 2017, FDA approved new inhalation device, named TD-300/A developed by United Therapeutics Corporation, for use with Tyvas- Inhalation Solution. The first triple combination inhaler named Trimbow launched for COPD in August 2017 and in February 2018, Teva Pharmaceutical Industries Ltd. announced the commercial availability of QVAR RediHaler Inhalation Aerosol to patients in the US.

Benefits: The report provides complete details about the products offered by inhalation system companies in various therapeutic verticals. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth.

Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Table of Contents

1 Industry Outlook
1.1 Industry overview
1.2 Industry Trends

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Market Definition 
3.2 Advantages of inhalation systems
3.3 Limitations associated with inhalation systems
3.4 Segmented Addressable Market (SAM)
3.5 Trends of the US inhalation systems market
3.6 Related Markets
3.6.1 Sleep Apnea
3.6.2 Anesthesia
3.6.3 Pulmonary Medicine

4 Market Outlook
4.1 History of Inhalation systems
4.2 Market segmentation
4.3 PEST Analysis
4.4 Porter 5(Five) Forces

5 Market Characteristics
5.1 DRO – US Inhalation Systems Market Dynamics
5.1.1 Drivers Rising prevalence’s of respiratory diseases Favorable reimbursement Increasing geriatric population
5.1.2 Opportunities Advancement in technology Upsurge in the demand for home-care therapeutic devices
5.1.3 Restraints Side effects allied with drug inhalation Unattainability of solo effective inhaler device that can treat many disease conditions
5.2 DRO – Impact Analysis
5.3 Key Stakeholders

6 By Products: Market Size and Analysis
6.1 Overview
6.2 Inhalers
6.2.1 Dry powder inhalers
6.2.2 Metered dose inhaler
6.2.3 Soft mist inhaler
6.3 Nebulizers
6.3.1 Ultrasonic Nebulizers
6.3.2 Pneumatic/jet Nebulizers
6.3.3 Mesh Nebulizers

7 By Applications: Market Size and Analysis
7.1 Overview
7.2 Asthma
7.3 Chronic obstructive pulmonary disease (COPD)
7.4 Others

8 By End-Users: Market Size and Analysis
8.1 Overview
8.2 Hospitals
8.3 Ambulatory care centers
8.4 Home Care

9 Regions: Market Size and Analysis
9.1 Overview
9.2 United States

10 Competitive Landscape
10.1 Overview

11 Vendor Profiles
11.1 Boehringer Ingelheim GmbH
11.1.1 Overview
11.1.2 Business Units
11.1.3 Geographic Presence
11.1.4 Business focus
11.1.5 SWOT analysis
11.1.6 Business Strategy
11.2 Omron Corp.
11.2.1 Overview
11.2.2 Business Units
11.2.3 Geographic Presence
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 PARI GmbH
11.3.1 Overview
11.3.2 Business Focus
11.3.3 SWOT Analysis
11.3.4 Business Strategies
11.4 Philips Healthcare
11.4.1 Overview
11.4.2 Business Units
11.4.3 Geographic Presence
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategy
11.5 3M
11.5.1 Overview
11.5.2 Business Units
11.5.3 Geographic Presence
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategy

12 Companies to Watch For
12.1 AptarGroup, Inc.
12.1.1 Overview
12.2 Teleflex Incorporated
12.2.1 Overview
12.3 Agilent Technologies
12.3.1 Overview
12.3.2 Agilent Technologies, Inc.: Recent Developments
12.4 Inspiro Medical Ltd. (a subsidiary of Opko Health, Inc.)
12.4.1 Overview
12.4.2 Inspiro Medical Ltd: Recent Developments
12.5 Monaghan Medical Corporation
12.5.1 Overview
12.5.2 Monaghan Medical Corporation: Recent Developments
12.6 Astra Zeneca PLC
12.6.1 Overview
12.6.2 AstraZeneca PLC: Recent Developments
12.7 GlaxoSmithKline plc
12.7.1 Overview
12.7.2 Glaxosmithkline Plc: Recent Developments
12.8 TEVA Pharmaceuticals Industries Ltd
12.8.1 Overview
12.8.2 TEVA Pharmaceuticals Industries LTD.: Recent Developments
12.9 Beckton Dickinson and Company
12.9.1 Overview
12.9.2 Beckton Dickinson and Company: Recent Developments

13 Annexure
13.1 Abbreviations


Table 1 US Inhalation Systems Market Revenue By Application, 2017–2024 ($Million)
Table 2 Other Prominent Vendors Of Us Inhalation Systems Market
Table 3 Boehringer Ingelheim: Product Offerings
Table 4 Boehringer Ingelheim: Recent Developments
Table 5 Omron Corp.: Offerings
Table 6 Omron Corp.: Recent Developments
Table 7 Pari Gmbh: Product Offerings
Table 8 Pari Gmbh: Recent Developments
Table 9 Philips Healthcare: Offerings
Table 10 Philips Healthcare: Recent Developments
Table 11 3M: Product Offerings
Table 12 3M: Recent Developments
Table 13 Aptargroup, Inc.: Snapshot
Table 14 Aptargroup, Inc.: Recent Developments
Table 15 Teleflex Incorporated: Snapshot
Table 16 Teleflex Incorporated: Recent Developments
Table 17 Agilent Technologies, Inc.: Snapshot
Table 18 Inspiro Medical Ltd.: Snapshot
Table 19 Monaghan Medical Corporation: Snapshot
Table 20 Astrazeneca Plc: Snapshot
Table 21 Glaxosmithkline Plc: Snapshot
Table 22 Teva Pharmaceuticals Industries Ltd.: Snapshot
Table 23 Beckton Dickinson And Company: Snapshot


Chart 1 Research Methodology Of US Inhalation Systems Market
Chart 2 US Inhalation Systems Market Revenue, 2017–2024 ($Million)
Chart 3 Segmentation Of US Inhalation Systems Market
Chart 4 Pest Analysis Of US Inhalation Market
Chart 5 Porter 5 Forces On US Inhalation Systems Market
Chart 6 DRO – Impact Analysis Of US Inhalation Systems Market
Chart 7 Key Stakeholders
Chart 8 US Inhalation Systems Market By Product Segmentation, 2017 (%)
Chart 9 US Inhalation Systems Market By Product Segmentation, 2024 (%)
Chart 10 US Inhalers Market Forecast, 2017–2024 ($Million)
Chart 11 US Inhalers Market Share, By Type, 2017 (%)
Chart 12 US Inhalers Market Share, By Type, 2024 (%)
Chart 13 US Dry Powder Inhalers Market Forecast, 2017–2024 ($Million)
Chart 14 US Metered Dose Inhalers Market Forecast, 2017–2024 ($Million)
Chart 15 US Nebulizers Market Forecast, 2017–2024 ($Million)
Chart 16 US Nebulizers Market Share, By Type, 2017 (%)
Chart 17 US Nebulizers Market Share, By Type, 2024 (%)
Chart 18 US Ultrasonic Nebulizers Market Forecast, 2017–2024 ($Million)
Chart 19 US Pneumatic Nebulizers Market Forecast, 2017–2024 ($Million)
Chart 20 US Mesh Nebulizers Market Forecast, 2017–2024 ($Million)
Chart 21 US Inhalation Systems Market By Application Segmentation, 2017 (%)
Chart 22 US Inhalation Systems Market By End Users Segmentation, 2017 (%)
Chart 23 Inhalation Systems Market Revenue In United States, 2017–2024 ($Million)
Chart 24 Boehringer Ingelheim: Overview Snapshot
Chart 25 Boehringer Ingelheim: Business Units
Chart 26 Boehringer Ingelheim: Geographic Presence
Chart 27 Boehringer Ingelheim: Swot Analysis
Chart 28 Omron Corp.: Overview Snapshot
Chart 29 Omron Corp.: Business Units
Chart 30 Omron Corp.: Geographic Presence
Chart 31 Swot Analysis
Chart 32 Pari Medical Holdings Gmbh: Swot Analysis
Chart 33 Philips Healthcare: Overview Snapshot
Chart 34 Philips Healthcare: Business Units
Chart 35 Philips Healthcare: Geographic Presence
Chart 36 Philips Healthcare: Swot Analysis
Chart 37 3M: Overview Snapshot
Chart 38 3M: Business Units
Chart 39 3M: Geographic Presence
Chart 40 3M: Swot Analysis



Companies Mentioned

  • 3M
  • Agilent Technologies Inc.
  • AptarGroup Inc.
  • AstraZeneca PLC
  • Becton Dickinson
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Inspiro Medical Ltd.
  • Monaghan Medical Corporation
  • Omron Corp.
  • PARI GmbH
  • Philips Healthcare
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.